Abbonarsi

Are cost advantages from a modern Indian hospital transferable to the United States? - 19/06/20

Doi : 10.1016/j.ahj.2020.04.009 
F. Erhun, PhD a, b, R.S. Kaplan, PhD c, V.G. Narayanan, PhD c, K. Brayton, MD, JD, MS a, M. Kalani, MD a, M.C. Mazza, PhD a, C. Nguyen, MD, MS a, T. Platchek, MD a, B. Mistry, MD, MBA c, R. Mann, BA a, D. Kazi, MD, MS d, C. Pinnock, MD, MPH a, K.A. Schulman, MD, MBA a, J. Xue, MD, MPH a, D. Ballard, MD, MSPH, PhD, FACP e, M. Mack, MD e, B. James, MD a, f, G. Poulsen, MBA f, J. Punnen, MD g, D. Shetty, MD g, A. Milstein, MD, MPH a,
a Clinical Excellence Research Center, Stanford University, Stanford, CA 
b Cambridge Judge Business School, University of Cambridge, Cambridge, UK 
c Harvard Business School, Boston, MA 
d Department of Medicine, University of California, San Francisco, CA 
e Baylor Scott & White Health, Dallas, TX 
f Intermountain Healthcare, Salt Lake City, UT 
g Narayana Health, Bangalore, India 

Reprint requests: Arnold Milstein, MD, MPH, Clinical Excellence Research Center, Stanford University, 366 Galvez St #323, Stanford, California 94305-6015.Clinical Excellence Research CenterStanford University366 Galvez St #323StanfordCalifornia94305-6015

Abstract

Background

Multiple modern Indian hospitals operate at very low cost while meeting US-equivalent quality accreditation standards. Though US hospitals face intensifying pressure to lower their cost, including proposals to extend Medicare payment rates to all admissions, the transferability of Indian hospitals’ cost advantages to US peers remains unclear.

Methods

Using time-driven activity-based costing methods, we estimate the average cost of personnel and space for an elective coronary artery bypass graft (CABG) surgery at two American hospitals and one Indian hospital (NH). All three hospitals are Joint Commission accredited and have reputations for use of modern performance management methods. Our case study applies several analytic steps to distinguish transferable from non-transferable sources of NH’s cost savings.

Results

After removing non-transferable sources of efficiency, NH’s residual cost advantage primarily rests on shifting tasks to less-credentialed and/or less-experienced personnel who are supervised by highly-skilled personnel when perceived risk of complications is low. NH’s high annual CABG volume facilitates such supervised work “downshifting.” The study is subject to limitations inherent in case studies, does not account for the younger age of NH’s patients, or capture savings attributable to NH’s negligible frequency of re-admission or post-acute care facility placement.

Conclusions

Most transferable bases for a modern Indian hospital’s cost advantage would require more flexible American states’ hospital and health professional licensing regulations, greater family participation in inpatient care, and stronger support by hospital executives and clinicians for substantially lowering the cost of care via regionalization of complex surgeries and weekend use of costly operating rooms.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Disclosures. This case study of hospital costs and care delivery methods was exempted from review by the Stanford Institutional Review Board (IRB). It obtained IRB approval at Narayana Health and obtained an IRB quality improvement waiver from the IRB offices used by The Heart Hospital Baylor Plano and Intermountain Medical Center. Two employees at each hospital co-authored the study. Co-author Arnold Milstein is an uncompensated trustee of Intermountain Healthcare, a non-profit organization operating one of the hospitals.
 Alternate Contact: Susan Shum-Maxwell – shummax1@stanford.edu


© 2020  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 224

P. 148-155 - Giugno 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial
  • Hans-Dirk Duengen, Raymond J. Kim, Doron Zahger, Katia Orvin, Ran Kornowski, Dan Admon, Jiri Kettner, Avraham Shimony, Christiane Otto, Michael Becka, Friederike Kanefendt, Andres Iniguez Romo, Tal Hasin, Petr Ostadal, Gonzalo Calvo Rojas, Michele Senni, GROUP investigators of the CHIARA MIA 2 trial, Ivo Podpera, Hana Linkova, Petr Hajek, Johann Bauersachs, Niels Menck, Jan Fuisting, Sadrack Oumbe Tiam, Manuel Martinez Selles, Vicente Miro Palau, Mercedes Roque, Borja Ibanez, Yaron Arbel, Eugenia Nikolsky, Savina Nodari, Gian Carlo Silvio Marenzi, Felice Achilli, Bernhard Reimers
| Articolo seguente Articolo seguente
  • Sarcopenia and health-related quality of life in older adults after transcatheter aortic valve replacement
  • Abdulla A. Damluji, Gregory Rodriguez, Thomas Noel, Lakerria Davis, Vishal Dahya, Behnam Tehrani, Kelly Epps, Matthew Sherwood, Eric Sarin, Jeremy Walston, Karen Bandeen-Roche, Jon R. Resar, Todd T. Brown, Gary Gerstenblith, Christopher M. O'Connor, Wayne Batchelor

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.